首页> 外文期刊>European journal of pharmaceutical sciences >Biomarkers in epilepsy-A modelling perspective
【24h】

Biomarkers in epilepsy-A modelling perspective

机译:癫痫患者的生物标志物 - 一种建模的视角

获取原文
获取原文并翻译 | 示例
           

摘要

Biomarkers can be categorised from type 0 (genotype or phenotype), through 6 (clinical scales), each level representing a part of the processes involved in the biological system and drug treatment. This classification facilitates the identification and connection of information required to fully (mathematically) model a disease and its treatment using integrated information from biomarkers. Two recent reviews thoroughly discussed the current status and development of biomarkers for epilepsy, but a path towards the integration of such biomarkers for the personalisation of anti-epileptic drug treatment is lacking. Here we aim to 1) briefly categorise the available epilepsy biomarkers and identify gaps, and 2) provide a modelling perspective on approaches to fill such gaps. There is mainly a lack of biomarker types 2 (target occupancy) and 3 (target activation). Current literature typically focuses on qualitative biomarkers for diagnosis and prediction of treatment response or failure, leaving a need for biomarkers that help to quantitatively understand the overall system to explain and predict differences in disease and treatment outcome. Due to the complexity of epilepsy, filling the biomarker gaps will require collaboration and expertise from the fields of systems biology and systems pharmacology.
机译:生物标志物可以从0型(基因型或表型),通过6(临床尺度),每个级别代表生物系统和药物治疗中所涉及的过程的一部分。该分类有助于识别和连接完全(数学)模型疾病的信息及其使用来自生物标志物的综合信息的治疗。近两周彻底讨论了癫痫生物标志物的现状和发展,而是缺乏对抗癫痫药物抗癫痫药物的个性化的这种生物标志物融入的途径。在这里,我们的目标是1)简单地将可用的癫痫生物标志物分类并识别差距,2)提供填补这些差距的方法的建模视角。主要存在缺乏生物标志物类型2(目标占用)和3(目标激活)。目前的文献通常侧重于定性生物标志物进行诊断和预测治疗反应或失败,需要对生物标志物有助于定量地理解整体系统解释和预测疾病和治疗结果的差异。由于癫痫的复杂性,填补生物标志物差距需要从系统生物学和系统药理学领域的合作和专业知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号